Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Pharming   /   up naar 0,40

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

Laatste koers (eur) Verschil Volume
0,727   +0,011   (+1,47%) Dagrange 0,715 - 0,728 3.278.719   Gem. (3M) 4,8M

up naar 0,40

Volgen
7.526 Posts
Pagina: «« 1 ... 370 371 372 373 374 ... 377 »» | Laatste | Omlaag ↓
  4. [verwijderd] 16 mei 2017 07:26
    www.pharming.com/pharming-announces-r...

    Pharming announces refinancing of its existing debt by a single US$100 million debt facility on improved commercial terms
    Repayment of amortising convertible bonds eliminates risk of approximately 24% dilution

    Leiden, The Netherlands, 16 May 2017: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) announces that it has completed a new US$100 million finance agreement with Orbimed Advisors. This has been used to redeem the Amortizing Convertible Bonds due 2017/2018, and to refinance the Company’s senior debt facility with Silicon Valley Bank and Kreos Capital, together with the associated prepayment fees and the legal and other costs of the transaction. The loan, initially structured as a bridge facility will be replaced within 60 days by a full loan agreement with a maturity date of June 2021 under similar terms and conditions as described below.
  12. forum rang 5 antop 16 mei 2017 17:47
    Rob wacht morgen af Q1 dan zien we wel wie er gelijk heeft!
    Was een groene dag,lekker toch. je leent geen 100 miljoen als niet eerst ff in de boeken heb mogen kijken toch. Al krijg je 30% als het risico te groot is moet je niet doen...aan niemand geld uit lenen.
    12% is hoog,maar niet vreemd. Luister naar wat de Vries zegt voorkomen van 24% verwatering..
    Dus ik zie morgen vol vertrouwen de koers stijgen naar 0,40 en hoger.
  16. forum rang 5 antop 16 mei 2017 19:50
    100 milj krijg je niet zomaar na de crisis zeker niet. 12% voor risico ook niet zo gek voor dit bedrag.
    Zij hebben echt de Q1 cijfers kunnen inzien en de toekomst,waaroor dit bedrag ook nog eens 24% positief is voor huidige aandeelhouders. Dan kan je toch maar een conclusie trekken.....
    Morgen 0,40 en hoger.Door angst wachten meeste af aan de zijlijn,
    Maar morgen is ondanks de investering in personeel enz Gewoon een goede instap richting 0,40 en hoger...Voor iedereen een groen topdag morgen.
  18. [verwijderd] 17 mei 2017 01:23
    En dat ze creatief zijn met schulden kunnen omgaan dat blijkt uit zo'n beetje alles wat ze moeten doen om te overleven....Hopelijk komt het ooit tot een bedrijf dat bestaansrecht gaat krijgen..En dan zit je al LT belegger goed.. Zo niet dan kan je zelf wel invullen wat er met je centjes gebeurd!
  19. forum rang 5 antop 17 mei 2017 07:08
    Previous
    Pharming Group Interim Report on Financial Results for the First Quarter 2017

    Operating profitability achieved, with a 794% increase in revenues from product sales, demonstrating the benefits of reacquiring RUCONEST® commercialisation rights in the US

    Leiden, The Netherlands, 17 May 2017: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) presents its (unaudited) financial report for the quarter ended 31 March 2017.

    Operational highlights

    Strategic decision to reacquire commercial rights to sell RUCONEST® in North America accelerated the delivery of operating profitability
    On track with investment in US commercialization team
    On schedule to complete transition of services from Valeant Pharmaceuticals International, Inc. in the second quarter
    Positive EMA amendment to the marketing authorization in Europe to allow self-administration of RUCONEST® for HAE attacks with a new custom-designed RUCONEST® Administration Kit
    Financial highlights

    Net product sales increased by 794% to €15.2 million (2016: €1.7 million), mainly as a result of the combined effect of receiving all of the revenue from US product sales instead of the previous 30% supply share of net sales, as well as a significant underlying increase of US sales volumes.
    Total revenues increased by 605% to €15.5 million (including €0.3 million of license revenue) from €2.2 million in 2016 (including €0.5 million in license revenue)
    Operating results improved to a profit of €3.9 million from a loss of €3.2 million in 2016, and a loss of €11.5 million over the whole of 2016, despite a considerable increase in commercialization activities, especially in the US
    The net result was a loss of €5.7 million, compared with a loss of €3.4 million in 2016, mainly as a result of non-cash financing expenses required to be shown under IFRS associated with the Amortising Convertible Bonds 2017/2018
    The equity position improved from €27.5 million in December 2016 to €28.9 million at the end of March 2017, mainly due to the conversion of the early installments of the Amortizing Convertible Bond into shares and despite the net loss of €5.7 million
    Inventories changed from €17.9 million in 2016 to €18.9 million in 2017, largely due to the need to cover the improving sales level in the US and to preparation for the launch of the self-administration kits in Europe, as well as raw materials for the new forms of RUCONEST® in development
    Conversions by some bondholders during the quarter, together with scheduled repayments, meant that the amount of Amortizing Bonds outstanding prior to the refinance was reduced from €45.0 million to €36.6 million. No cash payment was required for the first installment of the Bonds due on 1 February 2017, only €125,000 was required for the second installment, paid on 1 March 2017, and €1.3 million was required for the third installment, paid on 31 March 2017.
    The Company’s cash position decreased from €32.1 million at year-end 2016 to €27.6 million at 31 March 2017 (€27.5 million at 31 March 2016), largely due to delayed receipt of some trade payments for the quarter, which were received after the quarter end in April, balanced by the lower-than-expected cash installments paid on the Amortizing Bonds. If these trade payments had been received during the quarter, the cash position would have increased, showing positive net cash generation.
    Post period highlights

    The refinance of the Company’s debt by means of 48 months senior secured debt from Orbimed Advisors has enabled the Company to recover 115.0 million shares net of new warrants, which were previously reserved for conversion and/or repayment of the Amortizing Bonds due in 2018, and has eliminated the need to repay part of these Bonds in shares at a significant discount to the current market price
    As expected, the refinancing will have a one-time negative impact on the net result for the second quarter as a result of the costs of the exercise as adjusted by the reversal of certain IFRS accounting entries in respect of the instruments which were refinanced. This will be rapidly recovered during the year as the benefits of the lower cash cost of debt and the recovery of the conversion shares, which could otherwise have been issued for less than the current market price of the Pharming shares, are realized
    The refinancing is currently structured as a bridge facility, and is expected to be replaced by a full facility with Orbimed Advisors within 60 days. The transaction has had almost no effect on Pharming’s cash position as at the reporting date. For more details see the relevant press release dated Tuesday 16 May 2017 on the Company’s website at www.pharming.com
    Click here to download the full press release

    print
    Share This Story, Choose Your Platform!
    FacebookTwitterLinkedinRedditTumblrGoogle+PinterestVkEmail
7.526 Posts
Pagina: «« 1 ... 370 371 372 373 374 ... 377 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Vertrek CEO overschaduwt goede resultaten Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. CEO: volop groeimotoren voor Pharming
  2. AEX opent waarschijnlijk hóger op Super Thursday met Besi, Unilever en Pharming
  3. Topman De Vries stopt bij Pharming
  4. Pharming start met Fase II klinische studie leniolisib
  5. Pharming: herstelpotentieel van 100%
  6. Slotcall: BAM en Pharming vinden gretig aftrek op groen gekleurd Damrak
  7. Micron-effect op de beurs? AEX gaat fraaie opening tegemoet, chipaandelen Azië vliegen
  8. Brits groen licht voor Joenja van Pharming
  9. Video: CEO tevreden over ontwikkelingen bij Pharming
  10. Dubbeltje op zijn kant voor AEX, terwijl cijferstorm aantrekt tot windkracht 10